Psychopharmacology

, Volume 225, Issue 2, pp 483–494 | Cite as

Pharmacological effects of cannabinoids on the reference and working memory functions in mice

  • Avdesh Avdesh
  • Yikai Hoe
  • Ralph N. Martins
  • Mathew T. Martin-Iverson
Original Investigation

Abstract

Rationale

Evidence indicates cannabinoid receptor agonists impair performance in procedures to assess memory that may also be confounded by motivational or motor effects, both of which occur with cannabinoids. Thus, convergence of evidence from a variety of procedures that differ in motivation, attention, arousal and response requirements, but share a common reliance on memory, is required. There are no current reports on cannabinoid effects on mice tested in the radial arm maze.

Objectives

The objective was to determine the effects of the cannabinoid agonist CP 55940 and the dependence of any such effects on the CB1 receptor using the CB1 receptor antagonist SR 141716A on two strains of mice in the eight-arm radial maze procedure.

Methods

Male C57BL/6J (N = 36) and C3H/HEJ (N = 12) mice were trained to a criterion and then were treated (IP) with vehicle + vehicle, SR 141716A + vehicle, vehicle + CP 55940 and SR 141716A + CP 55940 in a fully balanced mixed design prior to further tests in the maze. Reference (long-term) and working (short-term) memory were assessed.

Results

CP 55940 impaired performance of the reference memory task in the C57BL/6J strain but not the C3H/HEJ strain; SR 141716A reversed the effect of CP 55940 on these measures. CP 55940 also increased working memory errors in the C57BL/6J mice only, which was not affected by SR 141716A.

Conclusion

The present study provides evidence for a strain-specific effect of a dose of CP 55940 on reference memory. While the cannabinoid agonist also impaired working memory in one strain, this effect was apparently not mediated by CB1 receptors.

Keywords

Agonist Antagonist Associative learning Behaviour Cannabinoids Cognition Drug Learning and memory Maze 

Notes

Acknowledgments

We would like to thank the National Institute of Mental Health (NIMH) for their gracious donation of SR 141716A. AA is the recipient of a PhD scholarship from the Centre of Excellence for Alzheimer's Disease Research and Care and the School of Medical Sciences, Edith Cowan University. The authors would like to thank Kyran Graham for his constructive comments on an earlier version of this manuscript and Alix Mellor for her assistance in editing the manuscript.

References

  1. Abel EL (1971) Retrieval of information after use of marihuana. Nature 231:58PubMedCrossRefGoogle Scholar
  2. Abush H, Akirav I (2010) Cannabinoids modulate hippocampal memory and plasticity. Hippocampus 20:1126–1138PubMedCrossRefGoogle Scholar
  3. Akirav I (2011) The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci 5:34PubMedGoogle Scholar
  4. Avdesh A, Wong P, Martins RN, Martin-Iverson MT (2011) Memory function in a mouse genetic model of Alzheimer's disease. J Alzheimers Dis 25:433–444PubMedGoogle Scholar
  5. Avdesh A, Cornelisse V, Martin-Iverson MT (2012) Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats. Psychopharmacology (Berlin) 220:405–415CrossRefGoogle Scholar
  6. Berry EM, Mechoulam R (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 95:185–190PubMedCrossRefGoogle Scholar
  7. Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, Borowsky B, Stemmelin J, Cohen C, Pichat P, Arad M, Barak S, De Levie A, Weiner I, Griebel G, Varty GB (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berlin) 215:149–163CrossRefGoogle Scholar
  8. Block RI, Ghoneim MM (1993) Effects of chronic marijuana use on human cognition. Psychopharmacology (Berlin) 110:219–228CrossRefGoogle Scholar
  9. Braida D, Sala M (2000) Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. Neuroreport 11:2025–2029PubMedCrossRefGoogle Scholar
  10. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155–163PubMedGoogle Scholar
  11. Campos AC, Ferreira FR, Guimaraes FS, Lemos JI (2010) Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 167:238–246PubMedCrossRefGoogle Scholar
  12. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113–PL117PubMedCrossRefGoogle Scholar
  13. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586–594PubMedGoogle Scholar
  14. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose–response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berlin) 164:61–70CrossRefGoogle Scholar
  15. Darley CF, Tinklenberg JR, Roth WT, Atkinson RC (1974) The nature of storage deficits and state-dependent retrieval under marihuana. Psychopharmacology 37:139–149CrossRefGoogle Scholar
  16. Deacon RM, Rawlins JN (2006) T-maze alternation in the rodent. Nat Protoc 1:7–12PubMedCrossRefGoogle Scholar
  17. Devenport LD, Merriman VJ, Devenport JA (1983) Effects of ethanol on enforced spatial variability in the 8-arm radial maze. Pharmacol Biochem Behav 18:55–59PubMedCrossRefGoogle Scholar
  18. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822–825PubMedCrossRefGoogle Scholar
  19. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142:295–301PubMedCrossRefGoogle Scholar
  20. Ferrari F, Ottani A, Vivoli R, Giuliani D (1999) Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol Biochem Behav 64:555–561PubMedCrossRefGoogle Scholar
  21. Fletcher JM, Page JB, Francis DJ, Copeland K, Naus MJ, Davis CM, Morris R, Krauskopf D, Satz P (1996) Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 53:1051–1057PubMedCrossRefGoogle Scholar
  22. Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004) Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol Biochem Behav 77:567–573PubMedCrossRefGoogle Scholar
  23. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR (1992) A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 262:479–486PubMedGoogle Scholar
  24. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10–23PubMedCrossRefGoogle Scholar
  25. Hamamoto DT, Giridharagopalan S, Simone DA (2007) Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 558:73–87PubMedCrossRefGoogle Scholar
  26. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202PubMedCrossRefGoogle Scholar
  27. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322–328PubMedCrossRefGoogle Scholar
  28. Keeney BK, Raichlen DA, Meek TH, Wijeratne RS, Middleton KM, Gerdeman GL, Garland T Jr (2008) Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour. Behav Pharmacol 19:812–820PubMedCrossRefGoogle Scholar
  29. Lichtman AH, Martin BR (1996) Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126:125–131PubMedCrossRefGoogle Scholar
  30. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119:282–290PubMedCrossRefGoogle Scholar
  31. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247:1046–1051PubMedGoogle Scholar
  32. Mackie K, Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:E298–E306PubMedGoogle Scholar
  33. Mansbach RS, Rovetti CC, Winston EN, Lowe JA 3rd (1996) Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berlin) 124:315–322CrossRefGoogle Scholar
  34. Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C, Schmidhammer H, Viveros MP (2003) Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 74:649–656PubMedCrossRefGoogle Scholar
  35. Miller LL, Branconnier RJ (1983) Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull 93:441–456PubMedCrossRefGoogle Scholar
  36. Molina-Holgado F, Gonzalez MI, Leret ML (1995) Effect of delta9-tetrahydrocannabinol on short-term memory in the rat. Physiol Behav 57:177–179PubMedCrossRefGoogle Scholar
  37. Nakamura EM, Da Silva EA, Concilio GV, Wilkinson DA, Masur J (1991) Reversible effects of acute and long-term administration of D9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28:167–175PubMedCrossRefGoogle Scholar
  38. Olton DS, Becker JT, Handelmann GE (1979) Hippocampus, space and memory. Behav Brain Sci 2:315–365Google Scholar
  39. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514–536PubMedCrossRefGoogle Scholar
  40. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, Navarrete F, Manzanares J (2011) Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36:1489–1504PubMedCrossRefGoogle Scholar
  41. Pamplona FA, Takahashi RN (2006) WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci Lett 397:88–92PubMedCrossRefGoogle Scholar
  42. Pamplona FA, Bitencourt RM, Takahashi RN (2008) Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 90:290–293PubMedCrossRefGoogle Scholar
  43. Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304–311PubMedCrossRefGoogle Scholar
  44. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180PubMedGoogle Scholar
  45. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMedGoogle Scholar
  46. Pertwee RG (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13:147–159PubMedCrossRefGoogle Scholar
  47. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909–915PubMedCrossRefGoogle Scholar
  48. Ranganathan M, D’Souza DC (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berlin) 188:425–444CrossRefGoogle Scholar
  49. Reche I, Fuentes JA, Ruiz-Gayo M (1996) A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 301:75–81PubMedCrossRefGoogle Scholar
  50. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244PubMedCrossRefGoogle Scholar
  51. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere JC, Le Fur G (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941–1947PubMedCrossRefGoogle Scholar
  52. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483–501PubMedCrossRefGoogle Scholar
  53. Romero EM, Fernandez B, Sagredo O, Gomez N, Uriguen L, Guaza C, De Miguel R, Ramos JA, Viveros MP (2002) Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res 136:85–92PubMedCrossRefGoogle Scholar
  54. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91:383–388PubMedCrossRefGoogle Scholar
  55. Scholes KE, Martin-Iverson MT (2009) Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits. Psychopharmacology (Berlin) 207:469–484CrossRefGoogle Scholar
  56. Scholes KE, Martin-Iverson MT (2010) Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med 40:1635–1646PubMedCrossRefGoogle Scholar
  57. Scholes-Balog KE, Martin-Iverson MT (2011) Cannabis use and sensorimotor gating in patients with schizophrenia and healthy controls. Hum Psychopharmacol (in press)Google Scholar
  58. Solowij N, Stephens RS, Roffmans RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287:1123–1131PubMedCrossRefGoogle Scholar
  59. Stanley-Cary CC, Harris C, Martin-Iverson MT (2002) Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. Behav Pharmacol 13:15–28PubMedCrossRefGoogle Scholar
  60. Taylor CL, Kozak R, Latimer MP, Winn P (2004) Effects of changing reward on performance of the delayed spatial win-shift radial maze task in pedunculopontine tegmental nucleus lesioned rats. Behav Brain Res 153:431–438PubMedCrossRefGoogle Scholar
  61. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332PubMedCrossRefGoogle Scholar
  62. Varvel S, Hamm R, Martin B, Lichtman A (2001) Differential effects of a delta-sup-9-THC on spatial reference and working memory in mice. Psychopharmacology 157:142–150PubMedCrossRefGoogle Scholar
  63. Wegener N, Kuhnert S, Thuns A, Roese R, Koch M (2008) Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. Psychopharmacology (Berlin) 198:375–385CrossRefGoogle Scholar
  64. Wiley JL, Martin BR (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57–63PubMedCrossRefGoogle Scholar
  65. Willott JF (2001) Handbook of mouse auditory research: from behaviour to molecular biology. CRC Press, Boca RatonCrossRefGoogle Scholar
  66. Wise LE, Thorpe AJ, Lichtman AH (2009) Hippocampal CB(1) receptors mediate the memory impairing effects of delta(9)-tetrahydrocannabinol. Neuropsychopharmacology 34:2072–2080PubMedCrossRefGoogle Scholar
  67. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5780–5785PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Avdesh Avdesh
    • 1
    • 3
  • Yikai Hoe
    • 2
  • Ralph N. Martins
    • 1
    • 3
  • Mathew T. Martin-Iverson
    • 1
    • 2
    • 3
  1. 1.Centre of Excellence for Alzheimer’s Disease Research and CareEdith Cowan UniversityPerthAustralia
  2. 2.School of Medicine and PharmacologyThe University of Western AustraliaPerthAustralia
  3. 3.Centre for Clinical Research in Neuropsychiatry, Graylands HospitalThe University of Western AustraliaPerthAustralia

Personalised recommendations